Published in Gastroenterology on February 01, 1986
Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy | NCT02505009
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut (2001) 4.12
Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol (2008) 3.34
Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut (2003) 2.96
Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut (2004) 2.59
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
Staging systems in hepatocellular carcinoma. HPB (Oxford) (2005) 1.71
Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One (2012) 1.24
Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol (2005) 1.22
Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer (2013) 1.21
Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) (2008) 1.20
Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol (2005) 1.09
'Hepatoma-specific' alphafetoprotein may permit preclinical diagnosis of malignant change in patients with chronic liver disease. Br J Cancer (1997) 1.08
Validation of the 7th edition TNM staging system for hepatocellular carcinoma: an analysis of 8,828 patients in a single medical center. Dig Dis Sci (2013) 1.01
Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer. Ann Surg (1995) 0.99
Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol (2006) 0.97
Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World J Gastroenterol (2013) 0.96
Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis. Ann Surg (1998) 0.96
Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol (2005) 0.95
Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int (2007) 0.94
Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev (2005) 0.93
Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer (2003) 0.91
A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B. World J Gastroenterol (2001) 0.90
Liver Imaging Reporting and Data System: an expert consensus statement. J Hepatocell Carcinoma (2017) 0.88
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol (2006) 0.88
Efficacy of combination treatment--(TAE with adriamycin and ethanol)--for hepatocellular carcinoma. Cancer Chemother Pharmacol (1992) 0.87
Evaluation of impact of serial hepatitis B virus DNA levels on development of hepatocellular carcinoma. J Clin Microbiol (2009) 0.86
Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer (2006) 0.86
Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int (2010) 0.86
High expression of neuro-oncological ventral antigen 1 correlates with poor prognosis in hepatocellular carcinoma. PLoS One (2014) 0.85
The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer Network. Medicine (Baltimore) (2016) 0.83
Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus-related hepatocellular carcinoma. PLoS One (2014) 0.82
Disease burden of chronic hepatitis B among immigrants in Canada. Can J Gastroenterol (2013) 0.81
Screening for hepatocellular carcinoma. Review and perspective. West J Med (1988) 0.80
Outcomes of 116 patients with hepatocellular carcinoma. Cancer Chemother Pharmacol (1994) 0.80
Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure. World J Gastroenterol (2014) 0.76
Significance of hepatitis B virus surface antigen, hepatitis C virus expression in hepatocellular carcinoma and pericarcinomatous tissues. World J Gastroenterol (2007) 0.76
Transcatheter arterial chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol (1992) 0.76
Transcatheter arterial chemoembolization for hepatocellular carcinoma. Cancer Chemother Pharmacol (1989) 0.76
Ambovex(®) as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial. J Hepatocell Carcinoma (2015) 0.75
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines? J Korean Med Sci (2011) 0.75
Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments. World J Surg Oncol (2016) 0.75
The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma. Surg Today (2014) 0.75
Laparoscopic findings of reddish markings predict hepatocellular carcinoma in patients with hepatitis B virus-related liver disease. J Gastroenterol (2010) 0.75
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet (2003) 13.79
A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med (1998) 9.03
Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health (1999) 5.21
Methods for analyzing health care utilization and costs. Annu Rev Public Health (1999) 3.63
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology (2000) 3.58
Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (1999) 3.11
Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs (2000) 2.82
The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (1988) 2.75
Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol (1997) 2.66
Penalized Estimating Functions and Variable Selection in Semiparametric Regression Models. J Am Stat Assoc (2008) 2.50
Nonparametric analysis of recurrent events and death. Biometrics (2000) 2.49
Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst (2000) 2.23
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (1999) 2.16
The use of inferred haplotypes in downstream analyses. Am J Hum Genet (2007) 2.16
Eosinophilic gastroenteritis: 10 years experience. Am J Gastroenterol (1993) 2.15
Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst (2001) 2.11
Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology (1997) 2.06
Allergic rhinitis and risk of erectile dysfunction--a nationwide population-based study. Allergy (2013) 2.04
Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology (1987) 2.02
Identity of a novel swine hepatitis E virus in Taiwan forming a monophyletic group with Taiwan isolates of human hepatitis E virus. J Clin Microbiol (1999) 1.99
The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med (1996) 1.98
Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology (2000) 1.96
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology (1988) 1.91
Liver biochemical tests and dengue fever. Am J Trop Med Hyg (1992) 1.89
Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol (1997) 1.83
Possible transplacental transmission of human papillomaviruses. Am J Obstet Gynecol (1992) 1.80
The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport. J Virol (1990) 1.79
Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology (1991) 1.78
Semiparametric analysis of recurrent events data in the presence of dependent censoring. Biometrics (2003) 1.78
Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology (1995) 1.75
Anomalous synthesis of ppGpp in growing cells. Cell (1977) 1.72
Survival analysis in clinical trials: past developments and future directions. Biometrics (2000) 1.70
Is the p53 gene mutation of prognostic value in hepatocellular carcinoma after resection? Arch Surg (2000) 1.68
Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol (1997) 1.66
A gene involved in the metabolic control of ppGpp synthesis. Mol Gen Genet (1978) 1.65
Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res (2001) 1.64
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology (2000) 1.62
Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology (2000) 1.62
Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut (1999) 1.60
Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol (2011) 1.57
Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis (2004) 1.55
Efficient association mapping of quantitative trait loci with selective genotyping. Am J Hum Genet (2007) 1.55
Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology (1997) 1.54
Goodness-of-fit methods for generalized linear mixed models. Biometrics (2005) 1.51
Genome-wide association study of bipolar I disorder in the Han Chinese population. Mol Psychiatry (2010) 1.49
Efficient semiparametric estimation of haplotype-disease associations in case-cohort and nested case-control studies. Biostatistics (2006) 1.49
Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology (1998) 1.47
High-resolution finite element models with tissue strength asymmetry accurately predict failure of trabecular bone. J Biomech (2000) 1.46
Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology (1985) 1.45
Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis (1994) 1.44
Regression methods for cost-effectiveness analysis with censored data. Stat Med (2005) 1.44
Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology (1983) 1.44
Increased prevalence of the Taq I A1 allele of the dopamine receptor gene (DRD2) in obesity with comorbid substance use disorder: a preliminary report. Pharmacogenetics (1996) 1.43
Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer (2000) 1.39
Effects of food restriction on mechanical properties of arterial system in adult and middle-aged rats. J Gerontol A Biol Sci Med Sci (1999) 1.39
A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology (1999) 1.38
Semiparametric transformation models with random effects for joint analysis of recurrent and terminal events. Biometrics (2008) 1.38
Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology (1991) 1.35
A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer (1993) 1.35
A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer (1988) 1.35
Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics (1995) 1.35
Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Gynecol Oncol (1996) 1.35
Identification of a novel strain of hepatitis E virus responsible for sporadic acute hepatitis in Taiwan. J Med Virol (1998) 1.34
Induction of VX2 carcinoma in rabbit liver: comparison of two inoculation methods. Lab Anim (2004) 1.34
Improvement in diabetes control with a monitoring system based on a hand-held, touch-screen electronic diary. J Telemed Telecare (2001) 1.34
The effect of human papillomavirus infection on sperm cell motility. Fertil Steril (1997) 1.33
Detecting haplotype effects in genomewide association studies. Genet Epidemiol (2007) 1.33
Order of injection of T7 bacteriophage DNA. J Virol (1973) 1.33
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology (1999) 1.32
An efficient resampling method for assessing genome-wide statistical significance in mapping quantitative trait Loci. Genetics (2004) 1.32
On rapid stimulation of P values in association studies. Am J Hum Genet (2005) 1.32
A powerful and robust method for mapping quantitative trait loci in general pedigrees. Am J Hum Genet (2005) 1.29
Stringent control of RNA synthesis in the absence of guanosine 5'-diphosphate-3'-diphosphate. J Biol Chem (1981) 1.28
Incremental net benefit in randomized clinical trials. Stat Med (2001) 1.26